Perioperative chemotherapy: when to use it, what to use, and why

David C Johnson; Raj S Pruthi; Michael E Woods

doi:10.1016/j.ucl.2013.01.001

Perioperative chemotherapy: when to use it, what to use, and why

Urol Clin North Am. 2013 May;40(2):183-95. doi: 10.1016/j.ucl.2013.01.001. Epub 2013 Feb 28.

Authors

David C Johnson¹, Raj S Pruthi, Michael E Woods

Affiliation

¹ Department of Urology, University of North Carolina, Chapel Hill, NC 27599-7235, USA.

PMID: 23540777
DOI: 10.1016/j.ucl.2013.01.001

Abstract

This article provides an overview of intravesical chemotherapy agents used for non-muscle invasive bladder cancer; summarizes the evidence on single-dose perioperative administration, induction therapy, and maintenance therapy; and briefly discusses ongoing research.

MeSH terms

Administration, Intravesical
Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / adverse effects
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Combined Modality Therapy
Deoxycytidine / administration & dosage
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Randomized Controlled Trials as Topic
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / surgery

Substances

Antimetabolites, Antineoplastic
Antineoplastic Agents
Deoxycytidine
Gemcitabine